BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 9, 2012, Pages

  Sancisi, Valentina ^a   Nicoli, Davide ^a   Ragazzi, Moira ^b   Piana, Simonetta ^b   Ciarrocchi, Alessia ^a  

^a Clinical Genetics Unit   (Italy)

^b Santa Maria Nuova Istituto di Ricovero e Cura A Carattere Scientifico Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GENOMIC DNA;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISTANT METASTASIS; DNA SEQUENCE; EXON; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; MALE; ONCOGENE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THYROID PAPILLARY CARCINOMA; V RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1;

ADULT; CARCINOMA, PAPILLARY; COHORT STUDIES; DNA, NEOPLASM; EXONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 84866184930     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1526     Document Type: Article

References (27)

1. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB 2010 Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819
2. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, Kurzrock R 2011 BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One 6:e25806
3. Caronia LM, Phay JE, Shah MH 2011 Role of BRAF in thyroid oncogenesis. Clin Cancer Res 17:7511-7517
4. Davies L, Welch HG 2010 Thyroid cancer survival in the United States: observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg 136:440-444
5. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A 2007 The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246:466-470; discussion 470-471
6. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, Basolo F 2007 Association of BRAFV600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 92:4085-4090 (Pubitemid 350074715)
7. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F 2008 BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15 year median follow-up study. J Clin Endocrinol Metab 93:3943-3949
8. Lin KL, Wang OC, Zhang XH, Dai XX Hu XQ, Qu JM 2010 The BRAF mutation is predictive of aggressive clinicopathology characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol 17:3294-3300
9. Ricarte-Filho J, Ganly I, Rivera M, Katabi N, Fu W, Tuttle RM, Fagin J, Ghossein RA 2012 Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, number of nodal metastasis and extra-nodal extension. Thyroid 22:575-584
10. Chakraborty A, Narkar A, Mukhopadhyaya R, Kane S, D'Cruz A, Rajan MG 2012 BRAF (V600E) mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr Pathol 23:83-93
11. Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo do H, Youn YK 2012 BRAF(V600E) mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg 36:310-317
12. Lee JH, Lee ES, Kim YS 2007 Clincopathologic significance of BRAFV600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110:38-46
13. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park do J 2012 The association of the BRAF (V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118:1764-1773
14. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A 2009 BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease free-survival. Endocr J 56:89-97
15. Eloy C, Santos J, Soares P, Sobrinho-Simöes M 2011 The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch 459:265-276
16. Cheng S, Serra S, Mercado M, Ezzat S, Asa SL 2011 A high through-put proteomic approach provides distinct signatures for thyroid cancer behaviour. Clin Cancer Res 17:2385-2394
17. Paulson L, Shindo M, Schuff K, Corless C 2012 The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 138:44-49
18. Sassolas G, Hafdi-Nejjari Z, Ferraro A, Decaussin-Petrucci M, Rousset B, Borson-Chazot F, Borbone E, Berger N, Fusco A 2012 Oncogenic alterations in papillary thyroid cancers of young patients. Thyroid 22:17-26
19. Handkiewicz-Junak D, Czarniecka A, Jarzab B 2010 Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol Cell Endocrinol 322:8-28
20. De Lellis RA, Lloyd RV, Heitz PU, Eng C, eds. 2004 World Health Organization Classification of Tumours. Pathology and genetics of tumors of endocrine organs. Lyon, France: IARC Press
21. Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzi G, Vitale M 2012 The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab 97:517-524
22. Sapio MR, Posca D, Troncone G, Pettinato G, Palombini L, Rossi G, Fenzi G, Vitale M 2006 Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 154:341-348
23. Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC, Cheng JT 2005 No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 63:461-466
24. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R 2006 Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13:455-464 (Pubitemid 43886668)
25. Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G 2008 BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 68:618-634 (Pubitemid 351388702)
26. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393-4397 (Pubitemid 37153748)
27. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA 2011 Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 121:4700-4711